Skip to main content
. 2016 Mar 27;7(19):27295–27306. doi: 10.18632/oncotarget.8422

Figure 2. PRL-3 inhibition reduces survival in human myeloma cell lines.

Figure 2

PRL-3 inhibitor I inhibited survival of the 5 human myeloma cell lines INA-6-WT (A), ANBL-6 (B), RPMI8226 (C), OH-2 (D) and IH-1 (E). Cells grown for 3-4 days in 10% FBS or 0,1% BSA (F) in RPMI with 1 ng/mL IL-6 (INA-6-WT and ANBL-6), 10% FBS in RPMI (RPMI8226) or 2% HS in RPMI with 1 ng/mL IL-6 (IH-1 and OH-2). Cell viability was measured with annexin-V binding and PI uptake (A–E) or CellTiterGlo Luminescent Cell Viability Assay (F) Relative luciferase units (RLU) reflect the amount of ATP detected in each well. ShPRL-3(1) and (2) refer to knock down with two different shRNAs against PRL3. Error bars represent +/− 2 SD of triplicate (A–E) or quintuple (F) measurements. Figure showing one representative experiment of three. Asterisks in (F) indicates P ≤ 0.01.